Physician profile
Jeri B Johnson
NPI 1689674111
$9,201.71
in general payments reported to CMS, 2019-2025
50 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $870 · 2021: $1,135 · 2022: $1,283 · 2023: $1,533 · 2024: $1,430 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.25 |
| Education | $161.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,914.85 | 2021-2025 | |
| Astellas Pharma US INC | $807.91 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $764.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $608.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.76 | 2019-2025 | Jardiance |
| Amgen INC. | $459.60 | 2019-2023 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $442.72 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $438.59 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $350.03 | 2019-2022 | |
| Abbott Laboratories | $254.95 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Merck Sharp & Dohme LLC | $235.46 | 2019-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $226.73 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $205.66 | 2019-2024 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $169.67 | 2019-2025 | Austedo Xr |
| Sumitomo Pharma America, INC. | $137.55 | 2023-2025 | Gemtesa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeri Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.